CD274 and hepatocellular carcinoma: Among these, immune checkpoint inhibitors, primarily PD-1/PD-L1 inhibitors, have opened up new avenues for neoadjuvant immunotherapy in HCC patients (10–12).The PD-1/PD-L1 pathway serves as a crucial mediator of local immune suppression within the tumor microenvironment (TME).